People living with HIV (PLWH) who are on protease inhibitor (PI)-containing regimens have been shown to have increases in visceral adipose tissue (VAT) and a greater decrease in spine bone mineral density (BMD) than those receiving non-PI regimens when initiating treatment. This increase in VAT has been hypothesized to falsely lower spine BMD measured via dual-energy X-ray absorptiometry, suggesting that the PI-associated BMD loss is an artefact rather than real. To test this, data collected from two completed 96-week clinical trials, AIDS Clinical Trial Group studies A5224s and A5260s, of antiretroviral therapy-naive PLWH initiating treatment with PI and non-PI-containing regimens were analyzed comparing VAT accumulation and spine BMD loss. Results showed no significant decrease in spine BMD in persons in the highest quartile (Q4) of VAT gain versus the rest of the study population (Q1–3) in either the PI and non-PI arms, suggesting that PI-associated BMD loss is not likely to be an artefact of overlying VAT.

中文翻译：

---

脂肪变化对蛋白酶抑制剂对开始抗逆转录病毒治疗后腰椎骨矿物质密度变化的影响。

与接受非 PI 方案的人相比，接受含蛋白酶抑制剂 (PI) 方案的 HIV 感染者 (PLWH) 的内脏脂肪组织 (VAT) 增加，脊柱骨矿物质密度 (BMD) 降低幅度更大在开始治疗时。据推测，VAT 的这种增加会错误地降低通过双能 X 射线吸收测定法测量的脊柱 BMD，这表明与 PI 相关的 BMD 损失是人为的，而不是真实的。为了验证这一点，我们分析了从两项已完成的 96 周临床试验（AIDS 临床试验组研究 A5224s 和 A5260s）中收集的数据，这些试验的抗逆转录病毒治疗初治 PLWH 开始使用 PI 和不含 PI 的方案进行治疗，比较 VAT 积累和脊柱 BMD 损失.